William Blair Has Negative Estimate for TPST FY2024 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – William Blair decreased their FY2024 earnings estimates for shares of Tempest Therapeutics in a report issued on Wednesday, November 13th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($1.45) for the year, down from their previous estimate of ($1.42). William Blair has a “Outperform” rating on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Tempest Therapeutics’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($2.26) EPS.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04).

A number of other equities research analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a report on Wednesday, November 13th. Piper Sandler reduced their price objective on Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tempest Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.00.

Tempest Therapeutics Stock Down 8.3 %

NASDAQ:TPST opened at $0.89 on Monday. Tempest Therapeutics has a 1-year low of $0.83 and a 1-year high of $6.00. The firm has a market capitalization of $22.43 million, a price-to-earnings ratio of -0.58 and a beta of -1.78. The stock has a fifty day simple moving average of $1.19 and a 200 day simple moving average of $1.92.

Institutional Trading of Tempest Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC boosted its position in shares of Tempest Therapeutics by 69.2% in the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after acquiring an additional 11,689 shares during the period. XTX Topco Ltd bought a new stake in Tempest Therapeutics in the third quarter valued at $34,000. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics in the 2nd quarter worth about $55,000. Empower Advisory Group LLC acquired a new stake in shares of Tempest Therapeutics during the third quarter worth approximately $49,000. Finally, Fullcircle Wealth LLC acquired a new stake in Tempest Therapeutics during the 3rd quarter valued at $87,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.